« Förderinformationen
Sie verwenden einen sehr veralteten Browser und können Funktionen dieser Seite nur sehr eingeschränkt nutzen. Bitte aktualisieren Sie Ihren Browser. http://www.browser-update.org/de/update.html
Joint Programming - JPIAMR -Innovations against antibiotic-resistant bacteria: new targets, compounds and tools. Fundamental, translational research, with the exception of clinical trials
Deutsches Zentrum für Luft- und Raumfahrt e. V. (DLR)
Die Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) hat am 11. Januar 2018 eine Förderbekanntmachung veröffentlicht. Ziel der Förderung ist es, neue Antibiotika und Therapien gegen resistente Bakterien zu entwickeln.
Gefördert werden ausschließlich multinationale Projekte. An jedem Antrag dürfen maximal sieben Arbeitsgruppen teilnehmen, die aus mindestens drei teilnehmenden Ländern kommen. Das Antragsverfahren ist zweistufig angelegt. In der ersten Stufe können bis zum 07. März 2018 Projektskizzen eingereicht werden.
Ansprechpartnerin und Ansprechpartner in Deutschland sind:
Dr. Barbara Junker (E-Mail: barbara.junker@dlr.de, Tel: 0228 3821-1274) und
Dr. Akin Akkoyun (E-Mail: akin.akkoyun@dlr.de, Tel: 0228 3821-1864)
beim DLR Projektträger.
The JPIAMR, in partnership with sixteen member countries; Belgium, Czech Republic, Egypt, Finland, France, Germany, Ireland, Israel, Italy, Latvia, Norway, Poland, Romania, Spain, Sweden and Switzerland, is launching a sixth joint call for transnational research projects.
The call targets research in the following topic:

The primary aim of the 6th joint call of the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR) is to combine the resources, infrastructures, and research strengths of multiple countries in order to address the identification and validation of new targets, the development of new therapies, and new tools for new treatments (including new antibiotics).
The goal is to foster multinational research collaborations to add value to, and to build upon, the research conducted independently at national level, as well as to work together to develop new and urgently needed therapies.
The call will only cover research tackling the bacterial pathogens and the resistances identified in the Global priority list of antibiotic-resistant bacteria published by the WHO in September 2017 with the addition of multi- and extensively drug resistant Mycobacterium tuberculosis.
It is expected that through international collaborations combining complementary and synergistic research strengths, this JPIAMR call will contribute to the urgent need to curb the burden associated with the most prioritised infections. It is also a topic area suitable to reinforce academic - industry collaborations. The participation of industry is encouraged. The results of the funded projects should have an added value to society as a whole, the public health and finances by closing knowledge gaps and discovering new therapies. Although stand-alone projects are fully eligible, links with other European or international research programs and initiatives in the field will be of added value.

eitere Informationen: